Search

Your search keyword '"Aggarwal, Sanjay"' showing total 152 results
Start Over Author "Aggarwal, Sanjay"
152 results on '"Aggarwal, Sanjay"'

6. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Author

Cutler, Corey, primary, Lee, Stephanie J., additional, Arai, Sally, additional, Rotta, Marcello, additional, Zoghi, Behyar, additional, Lazaryan, Aleksandr, additional, Ramakrishnan, Aravind, additional, DeFilipp, Zachariah, additional, Salhotra, Amandeep, additional, Chai-Ho, Wanxing, additional, Mehta, Rohtesh, additional, Wang, Trent, additional, Arora, Mukta, additional, Pusic, Iskra, additional, Saad, Ayman, additional, Shah, Nirav N., additional, Abhyankar, Sunil, additional, Bachier, Carlos, additional, Galvin, John, additional, Im, Annie, additional, Langston, Amelia, additional, Liesveld, Jane, additional, Juckett, Mark, additional, Logan, Aaron, additional, Schachter, Levanto, additional, Alavi, Asif, additional, Howard, Dianna, additional, Waksal, Harlan W., additional, Ryan, John, additional, Eiznhamer, David, additional, Aggarwal, Sanjay K., additional, Ieyoub, Jonathan, additional, Schueller, Olivier, additional, Green, Laurie, additional, Yang, Zhongming, additional, Krenz, Heidi, additional, Jagasia, Madan, additional, Blazar, Bruce R., additional, and Pavletic, Steven, additional

Published
2021
Full Text
View/download PDF

8. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease

Author

Jagasia, Madan, primary, Lazaryan, Aleksandr, additional, Bachier, Carlos R., additional, Salhotra, Amandeep, additional, Weisdorf, Daniel J., additional, Zoghi, Behyar, additional, Essell, James, additional, Green, Laurie, additional, Schueller, Olivier, additional, Patel, Jeegar, additional, Zanin-Zhorov, Alexandra, additional, Weiss, Jonathan M., additional, Yang, Zhongming, additional, Eiznhamer, David, additional, Aggarwal, Sanjay K., additional, Blazar, Bruce R., additional, and Lee, Stephanie J., additional

Published
2021
Full Text
View/download PDF

11. Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Author

Cutler, Corey, primary, Lee, Stephanie J, additional, Arai, Sally, additional, Rotta, Marcello, additional, Zoghi, Behyar, additional, Ramakrishnan, Aravind, additional, Lazaryan, Aleksandr, additional, Eiznhamer, David A, additional, Schueller, Olivier, additional, Yang, Zhongming, additional, Green, Laurie S., additional, Aggarwal, Sanjay K, additional, Blazar, Bruce R., additional, Pavletic, Steven Z., additional, and Jagasia, Madan, additional

Published
2021
Full Text
View/download PDF

12. Results of an Open Label Dose Escalation Trial of AB-205 (E-CEL® cells) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Author

Budde, Lihua E., primary, Scordo, Michael, additional, Abedi, Mehrdad, additional, Mulroney, Carolyn, additional, Fakhri, Bita, additional, Pawarode, Attaphol, additional, Dholaria, Bhagirathbhai, additional, Shouse, Geoffrey, additional, Kavalerchik, Edward, additional, Aggarwal, Sanjay H., additional, Qazilbash, Muzaffar H., additional, Finnegan, Paul, additional, and Giralt, Sergio A, additional

Published
2021
Full Text
View/download PDF

15. Genome-Wide Association Study for Type 2 Diabetes in Indians Identifies a New Susceptibility Locus at 2q21

Author

Tabassum, Rubina, Chauhan, Ganesh, Dwivedi, Om Prakash, Mahajan, Anubha, Jaiswal, Alok, Kaur, Ismeet, Bandesh, Khushdeep, Singh, Tejbir, Mathai, Benan John, Pandey, Yogesh, Chidambaram, Manickam, Sharma, Amitabh, Chavali, Sreenivas, Sengupta, Shantanu, Ramakrishnan, Lakshmi, Venkatesh, Pradeep, Aggarwal, Sanjay K., Ghosh, Saurabh, Prabhakaran, Dorairaj, Srinath, Reddy K., Saxena, Madhukar, Banerjee, Monisha, Mathur, Sandeep, Bhansali, Anil, Shah, Viral N., Madhu, Sri Venkata, Marwaha, Raman K., Basu, Analabha, Scaria, Vinod, McCarthy, Mark I., Venkatesan, Radha, Mohan, Viswanathan, Tandon, Nikhil, and Bharadwaj, Dwaipayan

Published
2013
Full Text
View/download PDF

18. Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)

Author

Cutler, Corey, primary, Lee, Stephanie J., additional, Arai, Sally, additional, Rotta, Marcello, additional, Zoghi, Behyar, additional, Ramakrishnan, Aravind, additional, Eiznhamer, David, additional, Schueller, Olivier, additional, Yang, Zhongming, additional, Green, Laurie S., additional, Aggarwal, Sanjay K., additional, Blazar, Bruce R., additional, Pavletic, Steven Z., additional, and Jagasia, Madan, additional

Published
2020
Full Text
View/download PDF

19. Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Author

Scordo, Michael, primary, Budde, Lihua E, additional, Abedi, Mehrdad, additional, Mulroney, Carolyn, additional, Fakhri, Bita, additional, Pawarode, Attaphol, additional, Dholaria, Bhagirathbhai, additional, Kavalerchik, Edward, additional, Aggarwal, Sanjay K., additional, Qazilbash, Muzaffar H., additional, Finnegan, Paul, additional, and Giralt, Sergio A., additional

Published
2020
Full Text
View/download PDF

20. KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) – Long-Term Follow-up of a Phase 2a Study (KD025-208)

Author

Weisdorf, Daniel J., primary, Jagasia, Madan, additional, Salhotra, Amandeep, additional, Bachier, Carlos R., additional, Zoghi, Behyar, additional, Lazaryan, Aleksandr, additional, Essell, James H., additional, Green, Laurie S., additional, Schueller, Olivier, additional, Yang, Zhongming, additional, Eiznhamer, David A., additional, Aggarwal, Sanjay K., additional, Blazar, Bruce R., additional, and Lee, Stephanie, additional

Published
2020
Full Text
View/download PDF

21. Keeping it simple: smoke control in hospitality occupancies

Author

Moeller, Don and Aggarwal, Sanjay

Subjects
Business, Engineering and manufacturing industries
Abstract

Life safety code is evolving allow for a more performance-based design. Thus, a 'one size fits all' plan is now more inappropriate than ever, whether comparing two different buildings or [...]

Published
2004

22. Genome-wide association study for type 2 diabetes in Indians identifies a new susceptibility locus at 2q21

Author

Tabassum, Rubina, Chauhan, Ganesh, Dwivedi, Om Prakash, Mahajan, Anubha, Jaiswal, Alok, Kaur, Ismeet, Bandesh, Khushdeep, Singh, Tejbir, Mathai, Benan John, Pandey, Yogesh, Chidambaram, Manickam, Sharma, Amitabh, Chavali, Sreenivas, Sengupta, Shantanu, Ramakrishnan, Lakshmi, Venkatesh, Pradeep, Aggarwal, Sanjay K, Ghosh, Saurabh, Prabhakaran, Dorairaj, Srinath, Reddy K, Saxena, Madhukar, Banerjee, Monisha, Mathur, Sandeep, Bhansali, Anil, Shah, Viral N, Madhu, Sri Venkata, Marwaha, Raman K, Basu, Analabha, Scaria, Vinod, McCarthy, Mark I, DIAGRAM, INDICO, Venkatesan, Radha, Mohan, Viswanathan, Tandon, Nikhil, and Bharadwaj, Dwaipayan

Subjects
India, Membrane Proteins, Nerve Tissue Proteins, Middle Aged, Polymorphism, Single Nucleotide, White People, Asian People, Diabetes Mellitus, Type 2, Genetic Loci, Chromosomes, Human, Pair 2, Humans, Genetic Predisposition to Disease, Insulin Resistance, Aged, Genome-Wide Association Study
Abstract

Indians undergoing socioeconomic and lifestyle transitions will be maximally affected by epidemic of type 2 diabetes (T2D). We conducted a two-stage genome-wide association study of T2D in 12,535 Indians, a less explored but high-risk group. We identified a new type 2 diabetes-associated locus at 2q21, with the lead signal being rs6723108 (odds ratio 1.31; P = 3.32 × 10⁻⁹). Imputation analysis refined the signal to rs998451 (odds ratio 1.56; P = 6.3 × 10⁻¹²) within TMEM163 that encodes a probable vesicular transporter in nerve terminals. TMEM163 variants also showed association with decreased fasting plasma insulin and homeostatic model assessment of insulin resistance, indicating a plausible effect through impaired insulin secretion. The 2q21 region also harbors RAB3GAP1 and ACMSD; those are involved in neurologic disorders. Forty-nine of 56 previously reported signals showed consistency in direction with similar effect sizes in Indians and previous studies, and 25 of them were also associated (P < 0.05). Known loci and the newly identified 2q21 locus altogether explained 7.65% variance in the risk of T2D in Indians. Our study suggests that common susceptibility variants for T2D are largely the same across populations, but also reveals a population-specific locus and provides further insights into genetic architecture and etiology of T2D.

Published
2018
Full Text
View/download PDF

23. KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208)

Author

Jagasia, Madan, primary, Salhotra, Amandeep, primary, Bachier, Carlos R., primary, Zoghi, MD, PhD, FACP, Behyar, primary, Lazaryan, Aleksandr, primary, Weisdorf, Daniel J., primary, Essell, James, primary, Green, Laurie S., primary, Schueller, Olivier, primary, Huang, Lindy, primary, Yang, Zhongming, primary, Eiznhamer, David, primary, Aggarwal, Sanjay K., primary, Blazar, Bruce R., primary, and Lee, Stephanie J., primary

Published
2019
Full Text
View/download PDF

25. KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) - Pharmacodynamics (PD) and Updated Results

Author

Jagasia, Madan, primary, Salhotra, Amandeep, additional, Bachier, Carlos R., additional, Essell, James H, additional, Weisdorf, Daniel J., additional, Lazaryan, Aleksandr, additional, Zoghi, Behyar, additional, Green, Laurie S, additional, Schueller, Olivier, additional, Zanin-Zhorov, Alexandra, additional, Weiss, Jonathan M, additional, Eiznhamer, David A, additional, Aggarwal, Sanjay K, additional, Blazar, Bruce R., additional, and Lee, Stephanie J., additional

Published
2019
Full Text
View/download PDF

31. KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results

Author

Jagasia, Madan, primary, Salhotra, Amandeep, additional, Bachier, Carlos R., additional, Essell, James, additional, Weisdorf, Daniel J., additional, Zoghi, Behyar, additional, Green, Laurie S., additional, Schueller, Olivier, additional, Zanin-Zhorov, Alexandra, additional, Weiss, Jonathan M., additional, Eiznhamer, David, additional, Aggarwal, Sanjay K., additional, Blazar, Bruce R., additional, and Lee, Stephanie J., additional

Published
2018
Full Text
View/download PDF

33. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Author

Ludwig, Heinz, primary, Dimopoulos, Meletios A., additional, Moreau, Philippe, additional, Chng, Wee-Joo, additional, Goldschmidt, Hartmut, additional, Hájek, Roman, additional, Facon, Thierry, additional, Pour, Ludek, additional, Niesvizky, Ruben, additional, Oriol, Albert, additional, Rosiñol, Laura, additional, Suvorov, Aleksandr, additional, Gaidano, Gianluca, additional, Pika, Tomas, additional, Weisel, Katja, additional, Goranova-Marinova, Vesselina, additional, Palumbo, Antonio, additional, Gillenwater, Heidi H., additional, Mohamed, Nehal, additional, Aggarwal, Sanjay, additional, Feng, Shibao, additional, and Joshua, Douglas, additional

Published
2017
Full Text
View/download PDF

34. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

Author

Dimopoulos, Meletios A., primary, Stewart, A. Keith, additional, Masszi, Tamás, additional, Špička, Ivan, additional, Oriol, Albert, additional, Hájek, Roman, additional, Rosiñol, Laura, additional, Siegel, David, additional, Mihaylov, Georgi G., additional, Goranova-Marinova, Vesselina, additional, Rajnics, Péter, additional, Suvorov, Aleksandr, additional, Niesvizky, Ruben, additional, Jakubowiak, Andrzej, additional, San-Miguel, Jesus, additional, Ludwig, Heinz, additional, Palumbo, Antonio, additional, Obreja, Mihaela, additional, Aggarwal, Sanjay, additional, and Moreau, Philippe, additional

Published
2017
Full Text
View/download PDF

35. Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Siegel, David S., primary, Oriol, Albert, additional, Rajnics, Peter, additional, Minarik, Jiri, additional, Hungria, Vania, additional, Lee, Jae Hoon, additional, Song, Kevin, additional, Obreja, Mihaela, additional, Aggarwal, Sanjay, additional, and Hajek, Roman, additional

Published
2017
Full Text
View/download PDF

36. Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)

Author

Facon, Thierry, primary, Lee, Jae Hoon, additional, Moreau, Philippe, additional, Niesvizky, Ruben, additional, Dimopoulos, Meletios Athanasios, additional, Hajek, Roman, additional, Osman, Muhtarjan, additional, Aggarwal, Sanjay, additional, Klippel, Zandra, additional, and San Miguel, Jesus, additional

Published
2017
Full Text
View/download PDF

37. Population Pharmacokinetics and Exposure–Response Relationship of Carfilzomib in Patients With Multiple Myeloma

Author

Ou, Ying, primary, Doshi, Sameer, additional, Nguyen, Anh, additional, Jonsson, Fredrik, additional, Aggarwal, Sanjay, additional, Rajangam, Kanya, additional, Dimopoulos, Meletios A., additional, Stewart, A. Keith, additional, Badros, Ashraf, additional, Papadopoulos, Kyriakos P., additional, Siegel, David, additional, Jagannath, Sundar, additional, Vij, Ravi, additional, Niesvizky, Ruben, additional, Graham, Richard, additional, and Visich, Jenn, additional

Published
2016
Full Text
View/download PDF

40. Performance enhancement of rectangular microstrip patch antenna using double H shaped metamaterial

Author

Kaur, Preet; YMCA University of Science and Technology, Faridabad, Aggarwal, Sanjay Kumar; YMCA University of Science and Technology, Faridabad, De, Asok; Delhi Technological University, Kaur, Preet; YMCA University of Science and Technology, Faridabad, Aggarwal, Sanjay Kumar; YMCA University of Science and Technology, Faridabad, and De, Asok; Delhi Technological University

Abstract

In this paper a high performance rectangular microstrip patch antenna (RMPA) has been designed using double H shaped metamaterial. First, the double H shaped metamaterial has been designed and optimized at 5.2 GHz resonant frequency of patch antenna. It has been found that embedding of this metamaterial into the substrate beneath the reference patch antenna improves its return loss and bandwidth without changing the resonant frequency and gain. To further enhance the gain and efficiency of the metamaterial embedded RMPA a superstrate of double H shaped metamaterial has been applied at the distance of λ/3 over it. Finally, a high gain, broadband and good impedance matched metamaterial inspired RMPA has been obtained. The proposed antenna was simulated and optimized using HFSS software. The prototype antenna has been fabricated and measured results of the proposed antenna are found to be in good agreement with the simulated results.

Published
2016

43. Carfilzomib (CFZ), carboplatin and etoposide for previously untreated extensive-stage small cell lung cancer (ES-SCLC): Phase 1b results from a phase 1b/2 study.

Author

Badin, Firas Benyamine, primary, Chiang, Anne C., additional, Fisher, William B., additional, Orlov, Sergey, additional, Harper, Harry D., additional, Eskander, Elhamy, additional, Harb, Wael A., additional, Kio, Ebenezer, additional, Gopalan, Priya Kadambi, additional, Haggstrom, Daniel Ernest, additional, Burdaeva, Olga, additional, Zahlten-Kumeli, Anita, additional, Aggarwal, Sanjay, additional, Obreja, Mihaela, additional, and Gorbunova, Vera, additional

Published
2016
Full Text
View/download PDF

45. Carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early progression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391).

Author

Ludwig, Heinz, primary, Dimopoulos, Meletios A., additional, Masszi, Tamas, additional, Spicka, Ivan, additional, Rocafiguera, Albert Oriol, additional, Hajek, Roman, additional, Rosinol, Laura, additional, Siegel, David Samuel DiCapua, additional, Mihaylov, Georgi, additional, Goranova-Marinova, Vesselina, additional, Rajnics, Peter, additional, Suvorov, Aleksandr, additional, Niesvizky, Ruben, additional, Jakubowiak, Andrzej J., additional, San Miguel, Jesus, additional, Obreja, Mihaela, additional, Aggarwal, Sanjay, additional, Moreau, Philippe, additional, and Palumbo, Antonio, additional

Published
2016
Full Text
View/download PDF

46. Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation: Secondary Analysis from the Phase 3 Aspire Study (NCT01080391)

Author

Hari, Parameswaran N., primary, Song, Kevin, additional, Bensinger, William, additional, Siegel, David, additional, Davies, Faith, additional, Huang, Mei, additional, Iskander, Karim, additional, Aggarwal, Sanjay, additional, and Abonour, Rafat, additional

Published
2016
Full Text
View/download PDF

50. Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.

Author

Ou, Ying, Doshi, Sameer, Nguyen, Anh, Jonsson, Fredrik, Aggarwal, Sanjay, Rajangam, Kanya, Dimopoulos, Meletios A., Stewart, A. Keith, Badros, Ashraf, Papadopoulos, Kyriakos P., Siegel, David, Jagannath, Sundar, Vij, Ravi, Niesvizky, Ruben, Graham, Richard, and Visich, Jenn

Subjects
COMBINATION drug therapy, DOSE-effect relationship in pharmacology, MULTIPLE myeloma, PHARMACOKINETICS
Abstract

A population pharmacokinetic (PK) model and exposure-response (E-R) analysis was developed using data collected from 5 phase 1b/2 and 2 phase 3 studies in subjects with multiple myeloma. Subjects receiving intravenous infusion on 2 consecutive days each week for 3 weeks (days 1, 2, 8, 9, 15, and 16) in each cycle at doses ranging from 15 to 20/56 mg/m2 (20 mg/m2 in cycle 1 and, if tolerated, escalated to 56 mg/m2 on day 8 of cycle 1). The population PK analysis indicated that among all the covariates tested, the only statistically significant covariate was body surface area on carfilzomib clearance; however, this covariate was unlikely to be clinically significant. Despite inclusion of different populations (relapsed or relapsed/refractory), treatments (carfilzomib monotherapy or combination therapy), infusion lengths (2 to 10 minutes or 30 minutes), and different doses, the E-R analysis of efficacy showed that after adjusting for baseline characteristics, higher area under the concentration-time curve was associated with improved overall response rate (ORR), from 15 to 20/56 mg/m2. No positive relationships between maximum concentration and ORR were identified, indicating that ORR would not be expected to be impacted by infusion length. For safety end points, no statistically significant relationship between exposure and increasing risk of adverse events was identified. The results of an E-R analysis provided strong support for a carfilzomib dose at 20/56 mg/m2 as a 30-minute infusion for monotherapy and combination therapy. This article illustrates an example of application of E-R analysis to support labeling dose recommendation in the absence of extensive clinical data. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results